Literature DB >> 23400861

Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus.

Jing Li1, Ying Shen, Jing He, Rulin Jia, Xiujie Wang, Xiaosan Chen, Dahai Wang, Lei Han, Lei Zhu, Xiaofeng Chi, Sandra Saschenbrecker, Cornelia Dähnrich, Winfried Stöcker, Wolfgang Schlumberger, Zhan-Guo Li.   

Abstract

BACKGROUND: This study aimed to evaluate autoantibodies against the native ribosomal P complex (anti-Rib-P(C)) and recombinant ribosomal P proteins (anti-Rib-P0, anti-Rib-P1, anti-Rib-P2) for their prevalence, diagnostic relevance and clinical associations in a Chinese cohort with systemic lupus erythematosus (SLE).
METHODS: Anti-Rib-P, anti-dsDNA and anti-Smith antigen (Sm) antibodies were analyzed in sera from 198 patients with SLE, 33 with rheumatoid arthritis, 61 with Sjögren's syndrome and 70 healthy individuals by means of ELISA.
RESULTS: Antibody prevalences were 29.8% (anti-Rib-P(C)), 33.3% (anti-Rib-P0), 42.9% (anti-Rib-P1) and 34.3% (anti-Rib-P2), at a specificity of 99%. Among SLE patients lacking anti-dsDNA and anti-Sm, 27.8% showed positive for at least one of the investigated anti-Rib-P types. The serological hit rate provided by anti-dsDNA/anti-Sm detection (72.7%) was increased upon parallel testing for anti-Rib-P(C) (77.3%) or anti-Rib-P0/P1/P2 (80.3%). Anti-Rib-P positivity was associated with disease activity, neuropsychiatric events, lupus nephritis, skin rash, lymphocytopenia, increased erythrocyte sedimentation rates, decreased complement C3/C4 and elevated IgA/IgG levels.
CONCLUSION: Based on these results, antibodies against ribosomal P proteins are important complementary parameters to anti-dsDNA and anti-Sm, and should be considered for inclusion in the classification criteria for SLE. The diagnostic value of anti-Rib-P0/P1/P2 is diagnostically superior to that of anti-Rib-P(C).
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23400861      PMCID: PMC6807460          DOI: 10.1002/jcla.21543

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  45 in total

1.  Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients.

Authors:  R Gerli; L Caponi; A Tincani; R Scorza; M G Sabbadini; M G Danieli; V De Angelis; M Cesarotti; M Piccirilli; R Quartesan; P Moretti; C Cantoni; F Franceschini; I Cavazzana; L Origgi; M Vanoli; E Bozzolo; L Ferrario; A Padovani; O Gambini; L Vanzulli; D Croce; S Bombardieri
Journal:  Rheumatology (Oxford)       Date:  2002-12       Impact factor: 7.580

2.  Restricted specificity of anti-ribosomal P antibodies to SLE patients in Israel.

Authors:  O Shovman; G Zandman-Goddard; B Gilburd; M Blank; M Ehrenfeld; S Bardechevski; L Stojanovich; P Langevitz; Y Shoenfeld
Journal:  Clin Exp Rheumatol       Date:  2006 Nov-Dec       Impact factor: 4.473

3.  Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture.

Authors:  K H Sun; S J Tang; M L Lin; Y S Wang; G H Sun; W T Liu
Journal:  Rheumatology (Oxford)       Date:  2001-07       Impact factor: 7.580

4.  International multicenter evaluation of autoantibodies to ribosomal P proteins.

Authors:  Michael Mahler; Kai Kessenbrock; Magdalena Szmyrka; Yoshinari Takasaki; Ignacio Garcia-De La Torre; Yehuda Shoenfeld; Falk Hiepe; Chen Shun-le; Carlos A von Mühlen; Henning Locht; Peter Höpfl; Allan Wiik; Westley Reeves; Marvin J Fritzler
Journal:  Clin Vaccine Immunol       Date:  2006-01

5.  Autoantibodies directed against ribosomal P proteins: use of a multiple antigen peptide as the coating agent in ELISA.

Authors:  L Caponi; S Pegoraro; V Di Bartolo; P Rovero; R Revoltella; S Bombardieri
Journal:  J Immunol Methods       Date:  1995-02-27       Impact factor: 2.303

6.  Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis.

Authors:  Morris Reichlin; Marianne Wolfson-Reichlin
Journal:  Clin Immunol       Date:  2003-07       Impact factor: 3.969

7.  Antiribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus.

Authors:  L S Teh; M K Lee; F Wang; M Manivasagar; P J Charles; G D Nicholson; E M Hay; D A Isenberg; N Amos; B D Williams
Journal:  Br J Rheumatol       Date:  1993-08

8.  Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus.

Authors:  I E A Hoffman; B R Lauwerys; F De Keyser; T W J Huizinga; D Isenberg; L Cebecauer; J Dehoorne; R Joos; G Hendrickx; F Houssiau; D Elewaut
Journal:  Ann Rheum Dis       Date:  2008-10-17       Impact factor: 19.103

9.  Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.

Authors:  J G Hanly; M B Urowitz; L Su; S-C Bae; C Gordon; A Clarke; S Bernatsky; A Vasudevan; D Isenberg; A Rahman; D J Wallace; P R Fortin; D Gladman; J Romero-Diaz; J Romero-Dirz; J Sanchez-Guerrero; M A Dooley; I Bruce; K Steinsson; M Khamashta; S Manzi; R Ramsey-Goldman; G Sturfelt; O Nived; R van Vollenhoven; M Ramos-Casals; C Aranow; M Mackay; K Kalunian; G S Alarcón; B J Fessler; G Ruiz-Irastorza; M Petri; S Lim; D Kamen; C Peschken; V Farewell; K Thompson; C Theriault; J T Merrill
Journal:  Ann Rheum Dis       Date:  2011-10       Impact factor: 19.103

10.  Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study.

Authors:  J G Hanly; M B Urowitz; F Siannis; V Farewell; C Gordon; S C Bae; D Isenberg; M A Dooley; A Clarke; S Bernatsky; D Gladman; P R Fortin; S Manzi; K Steinsson; I N Bruce; E Ginzler; C Aranow; D J Wallace; R Ramsey-Goldman; R van Vollenhoven; G Sturfelt; O Nived; J Sanchez-Guerrero; G S Alarcón; M Petri; M Khamashta; A Zoma; J Font; K Kalunian; J Douglas; Q Qi; K Thompson; J T Merrill
Journal:  Arthritis Rheum       Date:  2008-03
View more
  4 in total

1.  Detection of asymptomatic cranial neuropathies in patients with systemic lupus erythematosus and their relation to antiribosomal P antibody levels and disease activity.

Authors:  Wafaa Gaber; Yasser Ezzat; Neveen M El Fayoumy; Hanan Helmy; Abeer M Mohey
Journal:  Clin Rheumatol       Date:  2014-05-24       Impact factor: 2.980

Review 2.  Anti-ribosomal-P antibodies in lupus nephritis, neuropsychiatric lupus, lupus hepatitis, and Chagas' disease: promising yet limited in clinical utility.

Authors:  Mary Abraham; Chris T Derk
Journal:  Rheumatol Int       Date:  2014-06-07       Impact factor: 2.631

3.  Clinical and serological associations of anti-ribosomal P0 protein antibodies in systemic lupus erythematosus.

Authors:  Yong-Jun Mei; Peng Wang; Chao Jiang; Tao Wang; Lin-Jie Chen; Zhi-Jun Li; Hai-Feng Pan
Journal:  Clin Rheumatol       Date:  2017-11-18       Impact factor: 2.980

4.  Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies.

Authors:  Juan Irure-Ventura; Marcos López-Hoyos
Journal:  J Transl Autoimmun       Date:  2022-01-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.